Chemomab Therapeutics (NASDAQ:CMMB) Announces Quarterly Earnings Results

by · The Cerbat Gem

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) issued its earnings results on Thursday. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.28, FiscalAI reports.

Chemomab Therapeutics Stock Performance

Shares of Chemomab Therapeutics stock traded down $0.04 during midday trading on Thursday, reaching $1.70. 45,036 shares of the company’s stock traded hands, compared to its average volume of 43,345. The company has a market cap of $12.23 million, a PE ratio of -0.66 and a beta of 0.51. The stock has a 50 day moving average of $1.71 and a 200-day moving average of $1.94. Chemomab Therapeutics has a 12 month low of $1.35 and a 12 month high of $5.88.

Hedge Funds Weigh In On Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. XTX Topco Ltd acquired a new position in Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 19,013 shares of the company’s stock, valued at approximately $31,000. XTX Topco Ltd owned approximately 0.31% of Chemomab Therapeutics at the end of the most recent quarter. 46.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Friday, May 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $25.00.

Check Out Our Latest Research Report on CMMB

Chemomab Therapeutics Company Profile

(Get Free Report)

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.

Read More